Moderna (NASDAQ:MRNA) has reached a settlement worth up to $2.25 billion with Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV), and Arbutus Biopharma (NASDAQ:ABUS), resolving a patent dispute tied to its COVID-19 vaccine.
The agreement brings to an end multiple legal cases in the United States and internationally that alleged Moderna used lipid nanoparticle (LNP) delivery technology developed by Genevant and Arbutus in its vaccine without authorization.
Analysts at William Blair described the settlement as a constructive outcome for Moderna, noting that the resolution removes a major legal uncertainty and provides the company with greater financial clarity as it approaches several late-stage oncology trial readouts expected in 2026.